Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCε in the heart, which are mitigated by endothelin receptor antagonist CPU0213

Acta Pharmacologica Sinica

Volumn 30, Issue 8, 2009, Pages 1099-1106

  Cheng, Yu Si ^a   Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aminoguanidine; Endothelin receptor antagonists; Isoproterenol; MMP 9; NADPH oxidase; PKC

Indexed keywords

AMINOGUANIDINE; CPU 0213; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR; ISOPRENALINE; MESSENGER RNA; PROTEIN KINASE C EPSILON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EARLY RESPONSE GENE; GENE EXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; QT DISPERSION; RAT;

ANIMALS; CARDIOTONIC AGENTS; GENE EXPRESSION REGULATION; GUANIDINES; HEART; HYPERTROPHY; ISOPROTERENOL; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C-EPSILON; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN;

EID: 68349115897     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.104     Document Type: Article

References (41)

1. Wang HL, Dai DZ, Gao E, Zhang YP, Lu F. Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats. Acta Pharmacol Sin 2004; 25: 738-743 (Pubitemid 38736098)
2. Cheng YS, Dai DZ, Dai Y. Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. J Pharm Pharmacol 2009; 61: 569-576
3. Kassotis J, Mongwa M, Reddy CV. Effects of angiotensin-converting enzyme inhibitor therapy on QT dispersion post acute myocardial infarction. Pacing Clin Electrophysiol 2003; 26: 843-848 (Pubitemid 36442709)
4. Levantesi G, Scarano M, Marfisi R, Borrelli G, Rutjes AW, Silletta MG, et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol 2007; 100: 1644-1650 (Pubitemid 350122329)
5. Nessler J, Nessler B, Kitliński M, Libionka A, Kubinyi A, Konduracka E, et al. Sudden cardiac death risk factors in patients with heart failure treated with carvedilol. Kardiol Pol 2007; 65: 1417-1422
6. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95: 754-763
7. Goette A, Bukowska A, Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 2007; 7: 219-224 (Pubitemid 46404738)
8. Xie LH, Chen F, Karagueuzian HS, Weiss JN. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res 2009; 104: 79-86.
9. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005; 65: 230-238 (Pubitemid 40038496)
10. Zhang P, Hou M, Li Y, Xu X, Barsoum M, Chen Y, et al. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. Am J Physiol Heart Circ Physiol 2009; 296: H840-6.
11. Hunter JC, Korzick DH. Age- and sex-dependent alterations in protein kinase C (PKC) and extracellular regulated kinase 1/2 (ERK1/2) in rat myocardium. Mech Ageing Dev 2005; 126: 535-550
12. Zhao P, Li XG, Yang M, Shao Q, Wang D, Liu S, et al. Hypoxia suppresses the production of MMP-9 by human monocyte-derived dendritic cells and requires activation of adenosine receptor A2b via cAMP/PKA signaling pathway. Mol Immunol 2008; 45: 2187-2195
13. Xia QG, Na T, Guo YM, Bi YT, Zhang HY, Dai DZ. Improvement of chronic heart failure by dexamethasone is not associated with downregulation of leptin in rats. Acta Pharmacol Sin 2007; 28: 202-210 (Pubitemid 46155537)
14. Feng Y, Tang XY, Dai DZ, Dai Y. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta Pharmacol Sin 2007; 28: 1746-1754 (Pubitemid 350029324)
15. Li N, Jia N, Dai NZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: A role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-218
16. Iwasaki M, Hayashi Y, Kamibayashi T, Yamatodani A, Mashimo T. The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways. Br J Pharmacol 2008; 153: 1623-1630
17. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. N-S Arch Pharmacol 1999; 359: 212-219 (Pubitemid 29142872)
18. Feng Y, Dai DZ, Na T, Cui B, Wang T, Zhang Y, et al. Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy. Pharmacol Rep 2007; 59: 306-314
19. Chiu J, Xu BY, Chen S, Feng B, Chakrabarti S. Oxidative stressinduced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications. Can J Physiol Pharmacol 2008; 86: 365-372 (Pubitemid 351821130)
20. B of compound 0213. J China Pharm Univ 2004; 35: 552-557
21. B receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2009; 36: 169-175
22. Kyoi S, Otani H, Matsuhisa S, Akita Y, Enoki C, Tatsumi K, et al. Role of oxidative/nitrosative stress in the tolerance to ischemia/reperfusion injury in cardiomyopathic hamster heart. Antioxid Redox Signal 2006; 8: 1351-1361 (Pubitemid 44182433)
23. Xia HJ, Dai DZ, Dai Y. Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in L-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci 2006; 79: 1812-1819
24. Na T, Huang ZJ, Dai DZ, Zhang Y, Dai Y. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta Pharmacol Sin 2007; 28: 773-782 (Pubitemid 46817444)
25. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol 2007; 293: H2024-38. (Pubitemid 47605847)
26. Antzelevitch C. Heterogeneity and cardiac arrhythmias: an overview. Heart Rhythm 2007; 4: 964-972
27. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JD, Londoño C, Vos MA. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 2003; 59: 351-359 (Pubitemid 37272029)
28. Opthof T. In vivo dispersion in repolarization and arrhythmias in the human heart. Am J Physiol Heart Circ Physiol 2006; 290: H77-8.
29. Dai DZ. Two patterns of ion channelopathy in the myocardium: perspectives for development of anti-arrhythmic agents. Curr Opin Invest Drugs 2005; 6: 289-297
30. Dai DZ. CPU86017: a novel class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc Drug Rev 2006; 24: 101-115
31. Chelu MG, Wehrens XH. Sarcoplasmic reticulum calcium leak and cardiac arrhythmias. Biochem Soc Trans 2007; 35: 952-956
32. Huang F, Shan J, Reiken S, Wehrens XH, Marks AR. Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. Proc Natl Acad Sci USA 2006; 103: 3456-3461 (Pubitemid 43346490)
33. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004; 62: 9-33.
34. Cerrone M, Noujaim S, Jalife J. The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J Intern Med 2006; 259: 24-38.
35. Du RH, Yi HW, Dai DZ, Tang WH, Dai Y. Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent. J Pharm Pharmacol 2008; 60: 1089-1095
36. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115: 135-143 (Pubitemid 46136515)
37. Amir O, Paz H, Rogowski O, Barshai M, Sagiv M, Shnizer S, et al. Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients. Clin Cardiol 2009; 32: 199-203.
38. Hool LC. Evidence for the regulation of L-type Ca2+ channels in the heart by reactive oxygen species: mechanism for mediating pathology. Clin Exp Pharmacol Physiol 2008; 35: 229-234
39. Moshal KS, Rodriguez WE, Sen U, Tyagi SC. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008; 57: 379-384
40. Adiga IK, Nair RR. Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy. Cell Biochem Funct 2008; 26: 346-351
41. Cheng TH, Shih NL, Chen CH, Lin H, Liu JC, Chao HH, et al. Role of mitogen-activated protein kinase pathway in reactive oxygen species-mediated endothelin-1-induced beta-myosin heavy chain gene expression and cardiomyocyte hypertrophy. J Biomed Sci 2005; 12: 123-133 (Pubitemid 40576770)